And temsirolimus), inhibitors of Bcr-Abl (dasatinib, imatinib, and nilotinib), and inhibitors
And temsirolimus), inhibitors of Bcr-Abl (dasatinib, imatinib, and nilotinib), and inhibitors of Raf (sorafenib and vemurafenib) were 23.eight , 12.eight and 18.3 , respectively. Achievable pathogenesis of pruritus might involve…